10:28 AM
Dec 22, 2017
 |  BioCentury  |  Finance

Modulating mechanism

Why investors backed neurology company Aptinyx’s $70M series B

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials from NYX-2925 and a second compound in hand.

Bain Capital Life Sciences led the round. Fellow new investors Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management and Rock Springs Capital also participated, along with existing investors New Leaf...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >